SNAP Trial Finds Common Antibiotic Cefazolin as Effective as Standard Treatment for Serious Bloodstream Infections

New research published in the New England Journal of Medicine suggests cefazolin performs as well as flucloxacillin in treating a dangerous form of blood poisoning, and may cause less kidney damage in the process.

A Safer Route to the Same Result

A bloodstream infection caused by Staphylococcus aureus — the bacterium behind many hospital-acquired infections — is one of the most serious conditions a patient can face. It moves fast, it’s hard to treat, and getting the antibiotic choice right from the start can be the difference between recovery and death. So when a major clinical trial suggests a widely available, cheaper antibiotic works just as well as the long-established standard, clinicians sit up and take notice.

That’s exactly what the SNAP trial has found.

What the SNAP Trial Actually Tested

The New England Journal of Medicine — one of the most respected medical journals in the world — published the full results of the SNAP trial, which examined how cefazolin compared to flucloxacillin or cloxacillin in patients with methicillin-susceptible Staphylococcus aureus bacteraemia. That’s the specific strain of staph infection that hasn’t yet developed resistance to standard antibiotics, sometimes written as MSSA bacteraemia.

For their part, the headline finding: cefazolin was noninferior to flucloxacillin or cloxacillin when measuring 90-day mortality. In plain English, patients treated with cefazolin were no more likely to die within 90 days than those treated with the traditional drugs. But the difference that really stands out is what happened to the kidneys. Patients receiving cefazolin experienced fewer nephrotoxic effects — that is, less drug-related kidney damage — than those on flucloxacillin or cloxacillin.

Kidney damage during antibiotic treatment isn’t a minor side note. It can extend hospital stays, complicate recovery, and in vulnerable patients, trigger a cascade of further complications.

Why This Matters Beyond the Trial

Flucloxacillin has been the go-to treatment for MSSA bacteraemia in UK hospitals for decades. It works. But it comes with a demanding dosing schedule — typically given four times daily through an intravenous drip — and carries risks including liver toxicity alongside the kidney concerns. Cefazolin, by contrast, is generally considered easier to administer and has a longer track record in other countries as a first-line option.

The SNAP trial gives clinicians data to support a conversation that’s been happening quietly in infectious disease medicine for some time. According to the trial results as reported by the New England Journal of Medicine, the evidence now points toward cefazolin as a clinically sound alternative — not just a compromise.

And in an NHS already stretched thin, a treatment that’s effective, potentially less harmful, and logistically simpler to deliver is worth examining carefully.

—

Key Takeaways

• The SNAP trial found cefazolin was noninferior to flucloxacillin or cloxacillin in 90-day mortality outcomes for patients with MSSA bacteraemia
• Patients treated with cefazolin experienced fewer nephrotoxic (kidney-damaging) side effects than those on the standard treatments
• Results were published in the New England Journal of Medicine, one of the world’s leading peer-reviewed medical journals

What This Means for Kent Residents

For patients treated at Kent and Medway NHS hospitals, this research could eventually influence how serious bloodstream infections are managed on wards — though any changes to clinical protocols would be decided by NHS England and local trust guidelines, not by a single trial alone. If you or a family member are admitted to hospital with a suspected serious infection, it’s always reasonable to ask your clinical team about your treatment options and any associated risks. For general health concerns or questions about antibiotics, contact your GP or call NHS 111, which is available 24 hours a day. In a medical emergency, always call 999.